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Subverting the cell 
cycle 
Mitotix, Inc. 
For many years, cell cycle 
researchers have promised cancer 
cures on grant applications, while 
cancer researchers have turned up a 
growing list of proto-oncogenes with 
only tenuous links to the cell cycle. 
More recently, however, the number 
of known cell cycle proteins has shot 
up, and a number have been 
identified as culprits in cancer 
development. Companies such as 
Mitotix, Inc., of Cambridge, 
Massachusetts, are hoping to attack 
these new molecular targets, and so 
replace the present generation of 
toxic cancer therapeutics. 
Of cyclins, CDKs and cancer 
A group of protein kinases called the 
CDKs, and their obligatory cyclin 
partners, drive progression through 
the cell cycle (Figure 1). The father 
of all CDKs is Cd&, which acts 
primarily in G2 and mitosis. But the 
cyclin/CDK pairs involved in cancer 
are clustered just before the Gl- to 
S-phase transition, at the so-called 
restriction point. It is here that 
growth factors are needed to commit 
the cell to another round of DNA 
replication and cell division. 
The protein that has been most 
spectacularly implicated in cancer is 
neither a cyclin nor a CDK. p16 is 
one of a family of small CDK 
inhibitors: it’s specific target is the 
Cdk4/cyclin D complex. Initial 
reports of frequent p16 deletions 
were criticized, as they were based 
on the inspection of tumor cell lines, 
not primary tumors. But p16 has 
recovered its position of importance. 
Perhaps only the venerable ~53 is 
deleted in more cancers, and almost 
all cancers have defects in one 
component of the p16 pathway, 
which includes ~16, cyclin D, Cdk4, 
and the substrate of Cdk4 kinase 
activity, Rb. This is the most popular 
pathway for drug companies, 
including Mitotix. 
The cell cycle heads for S phase 
when Rb, now phosphorylated by 
Cdk4, releases members of the EZF 
family of transcription factors, so 
they are free to activate the 
transcription of a number of genes 
related to DNA synthesis. As cyclin 
D levels dwindle, CdkZ/cyclin E 
takes over the job of phosphorylating 
Rb and other substrates, putting the 
cell cycle past the point of mitogen 
dependence. Entry into S phase is 
complete once EZF activates the 
gene for cyclin A, which pairs with 
Cdk2 to keep DNA replication 
going. Elevated levels of cyclins A 
and E have also been detected in 
various cancers. 
Two CDK inhibitors can stop the 
orderly progression from cyclin D to 
E to A. ~27, which is present at high 
levels in quiescent cells, controls the 
decision to enter or exit the cycle in 
the first place. And ~21 is at least 
partly responsible for cell cycle arrest 
after DNA damage. The damage is 
somehow sensed by ~53, which 
activates ~21 and other proteins. 
Gentlemen, select your targets 
Mitotix is working on most of the cell 
cycle proteins commonly altered in 
cancer: Cdk4/cyclin D, ~16, 
CdkZ/cyclin E, ~27, ~53, and 
CdcZSA, which removes an inhibitory 
phosphate from human Cdk2. It has 
patents and license agreements 
covering a number of these proteins. 
“You want a target that drives the 
pathology of the disease,” explains 
Muzammil Mansuri, vice president 
of drug discovery at Mitotix. But this 
is a young field, and there are no 
rules for choosing drug targets. “If a 
molecule is altered [in cancer], does 
that necessarily mean it’s a good 
target?” asks Jim Roberts of the Fred 
Hutchinson Cancer Research Center 
in Seattle. “It makes it easier to 
understand what you’re going after: 
you’re going after the thing that is 
wrong in the cell. On the other hand, 
Figure 1 
Cell cycle targets involved in cancer. 
Proteins shown in blue are found at levels 
higher or lower than normal in cancer cells. 
Such proteins include all components of the 
plG/Cdk4/cyclin D pathway, including their 
downstream target, Rb. See text for further 
details. 
you may be inhibiting an essential 
process. From that perspective, it’s a 
less attractive target.” 
Selectivity - shutting down 
cancer cells more than healthy cells 
- is the key to cancer 
chemotherapy, and an area where 
current therapies do poorly. If CDK 
inhibitors block a process essential to 
all cells, will they be any better than 
DNA synthesis inhibitors? According 
to David Morgan of the University of 
California, San Francisco, “that 
question is often brushed aside.” 
The Seattle project, directed by 
Lee Hartwell and Steve Friend at 
the Fred Hutchinson Cancer 
Research Center, hopes to get 
around this problem by identifying 
genes that only become essential 
once other genes - those commonly 
deleted in cancer - are gone. Non- 
malignant cells, with the redundant 
genes A and B, would not be affected 
by a drug targeting gene A. 
But both Roberts and Morgan are 
hopeful that the Mitotix approach 
will also yield improved therapies. 
Mitotix should be encouraged, says 
Morgan, by the relatively minor 
problems experienced by mice 
deleted for one of the three cyclin D 
genes, a result that suggests that 
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many cells may get along just tine 
without these proteins. Other target 
proteins may be present in some 
tissues and not others, and so be 
uniquely good targets for certain 
cancers. But in the end, says Roberts, 
“you just can’t predict the outcome 
until you have a good inhibitor.” 
The Mitotix approach 
What is needed is a proof-of-concept 
experiment. Mitotix, and their 
collaborators at DuPont-Merck, are 
working on a mouse model of 
tumorigenesis in which p16 
production by the tumor can be 
turned on or off. “Such an animal 
could model the effect a Cdk4/cyclin 
Dl inhibitor may have on tumor 
cells,” says Mansuri. He says that the 
preliminary results obtained after 
inducing p16 expression in the tumor 
“appear to be quite positive.” 
The mouse is part of a 
collaboration between DuPont and 
Mitotix, which covers small molecule 
inhibitors of Cdk4/cyclin D and 
CdkZ/cyclin E, and mimetics of p16 
and ~27. Mitotix is concentrating on 
the biology and assay development, 
and leaving large-scale chemistry and 
screening to DuPont. Mitotix has 
recently patented various chromone 
derivatives, ATP-competitive ligands 
that reportedly inhibit cell 
proliferation. 
A similar agreement with BASF 
Pharma covers inhibitors of Cd&!5 
for the treatment of cancer. David 
Beach of Cold Spring Harbor 
Laboratory in New York, who in 199’2 
founded Mitotix with Giulio Draetta 
(now at the European Institute of 
Oncology in Milan), found that 
CDCZSA is an oncogene that is 
overproduced in many breast 
cancers. Mitotix has developed in 
vitro assays for the phosphatase 
activity of Cd&A, and in viva assays 
based on the ability of Cdc25A to 
induce the premature and lethal 
entry of fission yeast into mitosis. 
They have also isolated CDCZS 
homologs from Candida ahcans. The 
low level of similarity between 
human and fungal CDCZ homologs 
make this gene a good target for anti- 
fungal therapies. 
Another cell proliferation disorder 
is restenosis, the regrowth of cells 
lining blood vessels after balloon 
angioplasty. Mitotix plans to stop this 
growth with localized gene therapy, 
delivering either ~16 or ~27. 
An alternative to slowing cell 
division is inducing cell suicide, or 
apoptosis. ~53 stimulates apoptosis, 
especially once the pl6/Rb pathway 
is gone. But the cells of -90 % of 
cervical cancers fail to apoptose 
because E6, a papillomavirus protein, 
helps degrade ~53. When E6 is 
present, a cellular protein called E6- 
AP selects p53 as the target for 
ubiquitination and subsequent 
destruction. As proof-of-concept, 
Mitotix researchers have shown that 
~53 levels are raised through the use 
of antisense inhibitors of E6-Al? 
They have also isolated other 
proteins that bind in the E6/E6-AP 
complex, and are screening for 
inhibitors of ~53 ubiquitination. ~27 
degradation is also an interest, as 
Mitotix researchers discovered that 
~27 protein levels are controlled by 
modulating ubiquitin-mediated 
destruction. 
Cell cycle competitors 
Mitotix has chosen to straddle two of 
the most competitive fields: cancer 
therapeutics and cell cycle research. 
Not surprisingly, Mitotix has plenty of 
company. “There are hordes of them 
out there right now,” says Morgan. 
“Practically every pharmaceutical 
company has a CDK screen going 
on,” says Roberts. Cdk4 is the most 
popular anti-cancer target. It is the 
only enzyme in the vital p16 
pathway, which is the only pathway 
that is clearly before the restriction 
point. And Cdk4 is currently free 
from patent protection, as it was 
originally cloned as a PCR fragment 
and its importance not appreciated. 
Companies with screens for 
Cdk4/cyclin D inhibitors include 
Onyx (Richmond, California, with 
Parke-Davis), Novartis, Glaxo- 
Wellcome, Inc., Agouron 
Pharmaceuticals, Inc. (La Jolla, 
California), and Pharmacopeia, Inc. 
(Princeton, New Jersey). 
Although Cdk4 is in the public 
domain, Mitotix does have exclusive 
rights to cyclin D for drug discovery 
through its association with Beach and 
license agreements. Along with groups 
led by Andrew Arnold of Harvard’s 
Massachussetts General Hospital and 
Charles Sherr of St. Jude Children’s 
Research Hospital in Memphis, 
Beach’s group discovered cyclin D in 
1991. Given that conventional Cdk4 
activity assays require cyclin D, and 
that the cyclin D patent is yet to be 
isssued, the patent implications in this 
field are unresolved. 
Other companies are taking less 
conventional approaches. Onyx has 
removed a gene from adenovirus to 
target the virus to p53- cancer cells. 
The viral gene normally puts ~53 out 
of action, allowing the virus to grow 
in any cell. But the new virus can 
only grow in p53- cells. In human 
tumors grafted into nude mice, the 
new virus replicated in and lysed the 
tumor cells. 
David Lane of the University of 
Dundee has a new company, 
Cyclacel, which is focussing on his 
recent work on small peptides that 
disrupt protein-protein interactions 
in Gl/S. Finally, Bob Kerbel, of 
Sunnybrook Health Science Centre 
in Toronto, has worked with 
researchers at Gilead Sciences in 
Foster City, California, on a back-to- 
front strategy. They have shown that 
antisense inhibition of ~27, by 
accelerating the division of some 
slowly dividing cancer cells, can 
potentiate the killing of these cells 
by conventional anti-cancer drugs. 
More variations will follow. “By 
no means would I consider the 
CDKs the pinnacle of our 
capabilities in cell cycle research,” 
says Duncan Walker of Glaxo- 
Wellcome. “Within a year or so,” he 
says, there will be action aplenty. 
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